Beijing People's Hospital

Founded in 1918, Peking University People's Hospital is the first comprehensive Western medicine hospital built and managed by Chinese people. It was originally named “Beijing Central Hospital” and Dr. Wu Liande, the pioneer of modern Chinese medicine, was the first dean.


The development of Peking University People's Hospital is a testimony to China's medical progress. The hospital successfully carried out the first case in Asia and the fourth allogeneic syngeneic bone marrow transplant in the world. It gave birth to China's first hepatitis B vaccine and China's first extracorporeal shock wave lithotripsy equipment, which made an important contribution to the development of China's medical and health undertakings. contribution. After a century of development, it has become a modern comprehensive three-level hospital integrating medical, teaching and scientific research. It is the appointed hospital of the National Health and Wellness Committee, the affiliated hospital of Peking University, and the Second Clinical Medical College of Peking University.
The hospital has 4,204 employees on the job, 1,720 open beds, 48 ​​clinical departments, 17 medical technology departments, and 28 administrative functions.
Up to now, Peking University People's Hospital has received CAR-T immunotherapy for about 30 patients, and the overall effect is no less than that of foreign countries. The technology of Beijing Yongtai Biotechnology has been well used clinically.
The hospital's clinical, teaching and scientific research clusters are shoulder-to-shoulder. There are 11 national key disciplines of the Ministry of Education, 18 national health and family planning committees, 1 key laboratories of the Ministry of Education, 9 key laboratories of Beijing, 2 Beijing International Science and Technology Cooperation Base, 1 Beijing Clinical Medical Research Center, 5 Peking University Research Institutes, 6 Peking University Research Centers and 2 Peking University Medical Research Centers. At the same time, it is a national-level talent training model demonstration zone, a national-level specialty demonstration site, and a national-level teaching innovation team. In 2017, the hospital's critical medicine major won the bid for the “National Development and Reform Commission's ability to diagnose and treat difficult diseases”.
Peking University People's Hospital in the year of 2017, the number of patients in the emergency department was 2,867,200, and the total number of discharged patients was 81,893. The annual operation volume was 6,2015. The hospital has hematopoietic stem cell transplantation, organ transplantation, joint replacement, malignant tumor, bone and joint injury and spinal function reconstruction, chest minimally invasive surgery, retinal vitreous surgery, cardiovascular disease, liver disease, endocrine system disease, autoimmune disease, etc. The diagnosis and treatment of subject areas are at the leading level in China and even in the world

Safety and Efficacy Evaluation of IM19 CAR-T Cells


Assessment of the Safety and Feasibility of Administering T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor to Patients With CD19+ B-cell leukemia or CD19+ B-all.


Chimeric Antigen Receptor T Cells Targeting claudin18.2 in Solid Tumors.

Advanced Solid Tumor 北京

An open label, dose escalating/dose regimen finding clinical study to evaluate the safety, efficacy, and pharmacokinetics of autologous humanized anti-claudin18.2 chimeric antigen receptor T cell in advanced solid tumor.